Appropriate GMP for pharmaceutical Excipients

15-16 November 2016, Prague, Czech Republic

Course No. 15342



Dr Johanna Eisele, Evonik Industries AG, Germany

Ralf Gengenbach, Gempex, Germany

Dr Martin Melzer, Chemgineering Business Design GmbH, Germany

Dr Bernd Renger, Immediate Past Chair of the European QP Association; Renger Consulting, Germany

Rico Schulze, GMP/GDP Inspectorate, Germany


This course addresses the principles of appropriate GMP and GDP as laid down in the European Guideline on the formalised risk assessment for ascertaining the appropriate GMP for excipients. It aims to explain how to implement these principles to meet the requirements of the Guideline and the authorities’ expectations. Specialists from the industry and authority will share their expert knowledge on all important aspects with respect to appropriate GMP/GDP for pharmaceutical excipients.

You will learn

  • how appropriate GMP and GDP standards for excipients should look like,
  • how to perform a formalised risk assessment for pharmaceutical excipients,
  • how Quality Agreements between excipients suppliers and customers should be designed,
  • how the oversight of complex supply chains can be kept and what to do when an audit is not possible,
  • what authorities expect regarding excipients qualification.
In a workshop you will elaborate a risk assessments on practical examples.


According to the EU Directive 2001/83/EC all active pharmaceutical ingredients used in pharmaceutical manufacturing must be produced in compliance with current Good Manufacturing Practice (cGMP). However due to the complexity of the supply chains GMP and GDP requirements for excipients should be appropriate and not simply mirror those developed for APIs. Article 47 of Directive 2001/83/EC provides that “The Commission shall adopt guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients…” These guidelines are referred to in the second paragraph of point (f) of Article 46 of the Directive.

In March 2015 the Commission has published such Guidelines entitled “Guidelines on the formalised risk assessment for ascertaining the appropriate GMP for excipients of medicinal products for human use” according to which the manufacturing authorisation holders have now to perform a formalised risk assessment of the excipients used in their drug products and of the excipients manufacturer where they purchase the excipients. Based on this a control strategy has to be established in order to manage and mitigate the risks of use of the excipients.

Target Group

This course addresses to employees and senior staff of pharmaceutical companies and manufacturers of excipients The course is of particular interest to all those working in quality assurance, quality control laboratories, production and purchasing departments.


The European Guideline on appropriate GMP for Excipients – an introduction

  • History & Scope
  • Legal & International context (USP, WHO, other organizations)
  • Risk Analysis: GMP-requirements of excipient versus GMP-capability of excipient manufacturer
How to perform a formalised risk assessment
  • Step-by-Step practical approach
  • Ongoing risk review of excipient manufacturer & supplier
  • Embedding the Formalized Risk Assessment in overall context of existing supplier risk assessment
Suitable quality agreements in pharmaceutical excipients supply
  • Why quality agreements?
  • Objectives and contents of Quality Agreements
  • Negotiations of Quality Agreements – who should be involved?
  • Quality agreements with distributors and manufacturers
  • Quality agreements and commercial agreements
Suppliers, brokers, vendors – how to keep the oversight from supply chain mapping to qualification
  • Understand your excipient’s history
  • How to get information about excipient supply chains
  • What if … Rational qualification approaches
Audits at Excipients manufacturing sites
  • General auditing considerations
  • Basic requirements for excipient GMP inspections
  • Quality-critical processing steps
  • Audit check points
  • Audits at sites in Far East – what has to be considered?
What to do when an audit is not possible (or necessary)
  • Do we really always have to audit?
  • How to use the formalised risk assessment
  • Reliable sources of information
  • EXCiPACT™ and other initiatives
Appropriate GMP and GDP for pharmaceutical excipients – authorities’ expectations
  • Legal background of the guideline
  • Why do we need a European Guideline on a formalised risk assessment of Excipients?
  • Consequences of the Guideline
  • What does a GMP inspector expect of the Manufacturing Authorisation Holder?
Workshop: Performing Formalized Risk Assessments on practical examples
In this workshop the participants will have the opportunity to work on practical examples and elaborate risk assessments for various excipients. The elaborated solutions will be presented and discussed.


This course is part of the GMP Certification Programme "ECA Certified Quality Assurance Manager" Learn more

This training/webinar cannot be booked. Send us your inquiry by using the following contact form.

To find alternative dates for this training/webinar or similar events please see the complete list of all events.

For many training courses and webinars, there are also recordings you can order and watch any time. Just take a look at the complete list of all recordings.

* also payable by credit card
American Express Visa Mastercard

Further dates on-site
Further dates on-site
Not available
Further dates online
Further dates online
Not available
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023


“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024


“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024



“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023